Serial Number 98142436
730

Registration Progress

Application Filed
Aug 21, 2023
Under Examination
Oct 29, 2024
Approved for Publication
Sep 3, 2024
Published for Opposition
Sep 3, 2024
Registered

Attorney Assistance

Statement of Use Due - Extension 1 Granted
Due: Oct 29, 2025 107 days

Trademark Image

Basic Information

Serial Number
98142436
Filing Date
August 21, 2023
Published for Opposition
September 3, 2024
Drawing Code
2

Status Summary

Current Status
Active
Status Code
730
Status Date
Apr 24, 2025
Application
Pending
Classes
001 002 003 005
+2 more

Rights Holder

Immunolight, LLC

16
Address
6th Floor at Ford Field
1901 St. Antoine Street
Detroit, MI 48226

Ownership History

Immunolight, LLC

Original Applicant
16
Detroit, MI

Immunolight, LLC

Owner at Publication
16
Detroit, MI

Legal Representation

Attorney
J. Derek Mason

USPTO Deadlines

Next Deadline
107 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
October 29, 2025
Extension Available
Until October 29, 2025

Application History

30 events
Date Code Type Description Documents
Apr 25, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 25, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 24, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Apr 24, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 29, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 3, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 3, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 14, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 31, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 24, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 24, 2024 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Jul 24, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 16, 2024 CNFR R FINAL REFUSAL WRITTEN Loading...
May 16, 2024 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
May 16, 2024 GNFR O FINAL REFUSAL E-MAILED Loading...
May 1, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 30, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 30, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 30, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Jan 30, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Oct 31, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 31, 2023 GNRT O NON-FINAL ACTION E-MAILED Loading...
Oct 31, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 30, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Oct 30, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 30, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 26, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 20, 2023 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Sep 19, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 25, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 001
Chemical additives for altering color in cosmetic preparations; substances in the nature of chemicals for use in solar cells and photovoltaic cells
Class 002
Particulate energy converting additives for altering color in paint, pigment and colorant preparations; paint preparations in the nature of paints containing particulate energy converting additives for altering color; pigment preparations in the nature of pigments containing particulate energy converting additives for altering color; colorant preparations in the nature of colorants containing particulate energy converting additives for altering color
Class 003
Additives for altering color in cosmetic preparations, namely, coloring preparations and non-medicated skin care preparations; cosmetic preparations
Class 005
Pharmaceutical preparations for biological tissue regeneration; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of inflammation; pharmaceutical preparations for the treatment of brain disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of autoimmune disease and disorders; pharmaceutical agents for treating a disease, condition, or disorder of the tissues of a subject by detecting and triggering biophotons; pharmaceutical agents for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering intercellular communication; pharmaceutical agents for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering intracellular communication; pharmaceutical preparations for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering biophotons; pharmaceutical preparations for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering intercellular communication; pharmaceutical preparations for treating a disease, condition, and disorder of the tissues of a subject by detecting and triggering intracellular communication; preparations for sanitization and remediation of air supply, water supply, and biological materials for medical purposes
Class 009
Energy storage systems comprised of solar cells, photovoltaic cells and modules and any combination thereof; optical fibers for light or color transmission; optical communication networks comprised of optical fibers
Class 010
Medical device for detection of biophotons; medical device for detection of intercellular communication; medical device for detection of intracellular communication; medical device for treating a disease, condition and disorder by detection of intercellular communication; medical device for treating a disease, condition and disorder by detection of intracellular communication; medical device for triggering of biophotons; medical device for detection of intercellular communication; medical device for triggering of intracellular communication; medical device for treating a disease, condition and disorder by triggering of intercellular communication; medical device for treating a disease, condition and disorder by triggering of intracellular communication

Additional Information

Design Mark
The mark consists of three swirl designs that converge in the center of the image.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
001 002 003 005 009 010